



Patent Application  
Docket No. MDH-100XC1T  
Serial No. 09/939,161

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Simon J. Oh  
Art Unit : 1615  
Applicant : Richard W. Voellmy  
Serial No. : 09/939,161  
Filed : August 24, 2001  
For : Compositions and Methods Relating to Prevention of Chemotherapy-Induced Alopecia

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

DECLARATION OF RICHARD W. VOELLMY, Ph.D., Esq. UNDER 37 C.F.R. §1.132

Sir:

I, Richard W. Voellmy, Ph.D., of Pully, Switzerland, hereby declare:

THAT, my *curriculum vitae* is attached hereto as Exhibit A;

THAT, I am the named inventor on the above-referenced patent application (hereinafter referred to as "the patent application");

THAT, through my years of research, I have kept up to date on the technical literature and maintained contact with experts in the field by participating in professional meetings and seminars, and by direct personal contact. As a result, I am familiar with the general level of skill of those working in the fields of chemotherapy induced alopecia (hair loss);

THAT, I have read and understood the specification and claims of the patent application, the Office Actions dated February 26, 2003, August 12, 2003, May 6, 2004, October 5, 2004, October 7, 2005, and the references cited in the foregoing Office Actions;

AND, being thus duly qualified, do further declare:

C:\Documents and Settings\All Users\Documents\Eisenschienk Decla-Voellmy-rev.doc/DNB/

BEST AVAILABLE COPY

1. The Office Action has rejected claims 26-33 under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. In articulating the grounds of rejection, the Office Action argues that "[i]n methods of treating a condition, a time-dependence factor must be taken into account and that this factor cannot be easily predicted". The Office Action also argues that insufficient guidance and direction is provided to allow one skilled in the art to practice the claimed invention without undue experimentation. Finally, the Office Action argues that the specification fails to enable the claimed invention because there are no working examples and that one skilled in the art "would be burdened with undue 'painstaking experimentation study'" to practice the claimed invention.

2. While I do not agree that the specification fails to enable the claimed invention, I provide the following evidence demonstrating the effectiveness of the claimed invention in preventing hair loss (alopecia) in an animal model typically used for such studies using the methodologies described within the specification.

3. As described in the specification, animal models have been described in the literature that are suitable for such studies (see as-filed specification at page 21, line 10 through line 24). Rat/mouse models for the study of chemotherapy induced alopecia are useful because the animals demonstrate a follicular anagen phase that is comparable to humans (100% vs. 90%); the animals are responsive to chemotherapies alopecic in humans; the animals produce highly visible and definitive results; and the animals allow for the possibility to assess the chemotherapeutic effect of an agent on malignant cells introduced into the animal (see Appendix B, page 1).

4. Animals were treated as discussed in the specification (see, page 19, line 28 through page 21, line 8 and/or page 28, lines 25-32). For the experiment described herein, animals were randomized into groups and localized heat treatment was provided to one group 7 hours prior to chemotherapy. Localized heat treatment comprised contacting the scalp of the animals with a device that transferred heat (temperatures of about 39°C to about 45°C; specification at page 20, lines 15-

17) to a specific point on the animal's head for a period of time that ranged from about 15 minutes to about 120 minutes (specification at page 20, lines 15-17). VP16 (or etoposide; a chemotherapeutic agent) was injected intraperitoneally 2.5 µg/g. A second dose of chemotherapeutic agent was provided 24 hours later. Alopecia was recorded 7 days after initiation of chemotherapy. The experiments were then repeated. As demonstrated in Appendix B, page 2, localized heat treatment 7 hours prior to treatment with VP16 prevented alopecia at the site contacted with heat. Additional experiments were conducted with other chemotherapeutic agents with similar results (see Appendix B, page 3). As illustrated therein, chemotherapy-induced alopecia was reduced or prevented in animals treated with taxol (paclitaxel), cyclophosphamide, etoposide, and a combination of cyclophosphamide/adriamycin. Taxol was administered subcutaneously as no non-lethal dose could be found for intraperitoneal administration.

5. Animals were also assessed for the induction of heat shock protein as a result of treatment with heat. Animals were treated as described in the preceding paragraph and tissue samples were assayed for the induction of a heat shock protein response. Briefly, one day after heat treatment, skin sections from the nape of the neck of about 9-day old heat-treated Sprague-Dawley rats were taken from the heat-treated area or from the same area of the neck of non-heat treated animals. Skin sections were embedded in paraffin blocks and incubated with polyclonal mouse Hsp70 (5 µL/mL) for 1 hour. Sections were then incubated for 30 minutes with biotinylated anti-mouse IgG and sections were further incubated with avidinated peroxidase for 30 minutes. Slides were exposed to DAB and H<sub>2</sub>O<sub>2</sub> and counterstained with hematoxylin. As illustrated on page 4 of Appendix B, administration of heat to the animals resulted in the induction of a heat shock protein response that was associated with protection against chemotherapy-induced alopecia. Non-heat-treated animals showed little induction of heat shock protein.

6. Localized application of physical or chemical inducers do not appear to protect malignant/cancerous cells from chemotherapeutic agents. As illustrated in Appendix B, pages 5-7, the tumor cell line MIA C51 was administered intraperitoneally to animals. The animals were then

subjected to localized heat treatment followed by the administration of a chemotherapeutic agent (cyclophosphamide). As indicated at page 5 of Appendix B, malignant cells were not protected by localized application of heat to the animals. All animals that did not receive cyclophosphamide died within about 29 days after injection of the tumor cell line. The administration of cyclophosphamide to animals injected with the cancer cell line resulted in a decrease of the mortality rate. Thus, the localized application of heat to the animals did not appear to impact the sensitivity of cancer cells to cyclophosphamide.

7. Accordingly, it is respectfully submitted that one skilled in the art, using the teachings of the as-filed specification, would be able to practice the invention as claimed without being subjected to undue experimentation.

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or of any patent issuing thereon.

Further declarant sayeth naught.


Signed:

Richard W. Voellmy  
Richard W. Voellmy, Ph.D., Esq.

Date:

March 6, 2006

# **EXHIBIT A**



## **RICHARD VOELLMY**

Address: HSF Pharmaceuticals S.A., Avenue des Cerisiers 39B, CH-1009 Pully, Switzerland, Phone/Fax: 0041-21-728-0320, and  
Dept. of Biochemistry & Molecular Biology, University of Miami, 1011 N.W. 15 Street, Miami, FL 33136. Phone: (305) 243-5815. Facsimile: (305) 243-3064

### Education

Swiss Federal Institute of Technology, ETH-Zuerich, Switzerland, 1967-71, Diploma in Microbiology and Biochemistry

University of Zuerich, Switzerland, 1971-3, studies in Economics

Swiss Federal Institute of Technology, ETH-Zuerich, Switzerland, 1971-5, Doctorate in Microbiology and Biochemistry (Dr. Natw.)

University of Miami, School of Law (Night Program), Miami, FL, 1991-4, Juris Doctor

### Professional Experience

- |         |  |
|---------|--|
| 1971-5  | Graduate studies, Dept. of Microbiology, Swiss Federal Institute of Technology, ETH-Zuerich, Switzerland             |
| 1975-8  | Postdoctoral Fellow and (1978) Principal Research Associate, Dept. of Physiology, Harvard Medical School, Boston, MA |
| 1978-82 | Research Associate, Dept. of Molecular Biology, University of Geneva, Switzerland                                    |
| 1979    | Visiting Assistant Professor of Physiology, Harvard Medical School, Boston, MA                                       |
| 1982-3  | Assistant Professor, Dept. of Biochemistry, University of Miami, School of Medicine, Miami, FL                       |
| 1982-8  | Consultant to Battelle Memorial Institute, Geneva, Switzerland   |
| 1983-7  | Associate Professor, Dept. of Biochemistry, University of Miami, School of Medicine, Miami, FL                       |

1987-2004	Professor, Dept. of Biochemistry & Molecular Biology, University of Miami, School of Medicine, Miami, FL; Professor Emeritus since 2004.
1990	Co-Founder of StressGen Biotechnologies Corp., Victoria, B.C.
1995-1999	Vice-President for Planning and Intellectual Property, StressGen Biotechnologies Corp., & Member of its Scientific Advisory Board
1999-2000	Scientific Director, Debiopharm S.A., Lausanne, Switzerland
2000-present	Founder and Managing Director, HSF Pharmaceuticals S.A., Lausanne Switzerland
2005	Co-Founder of MedicalHeat S.A.

#### Professional Societies & Activities

American Society for Biochemistry & Molecular Biology  
 Florida Bar Association  
 Dade County Bar Association  
 U.S. Patent Bar  
 AIPLA  
 Editor, Cell Stress & Chaperones (-2003)  
 Guest Editor, Methods (2004)  
 Director, Ophthalmopharma A.G., Zuerich, Switzerland

#### Publications (abstracts omitted)

Voellmy, R., and Boellmann, F. (2006) Chaperone regulation of the heat shock protein response, in press

Voellmy, R. (2006) HSF1 and hsp gene regulation, in press

Tolson, J.K., Dix, D.J., Voellmy, R.W., and Roberts, S.M. (2006) Increased hepatotoxicity of acetaminophen in Hsp70i knockout mice, Toxicol Appl Pharmacol. 210: 157-162.

Voellmy, R. (2005) Feedback regulation of the heat shock response. In: Molecular Chaperones in Health and Disease (Gaestel, M. ed.), Handbook of Experimental Pharmacology, Springer Verlag, Heidelberg, Germany, pp. 43-68.

Vilaboa, N., Fenna, M., Munson, J., Roberts, S.M., and Voellmy, R. (2005) Novel gene switches for targeted and timed expression of proteins of interest. Mol. Ther.: 12: 290-298.

Guettouche, T., Boellmann, F., Lane, W.S., and Voellmy, R. (2005) Analysis of phosphorylation of human heat shock factor 1 in severely heat-stressed cells, *BMC Biochemistry* 6: 4.

Voellmy, R. (2005) The stress protein response: consequences of stress exposure – cytoprotection – potential diagnostic and therapeutic applications. *Methods* 35: 115-116.

Voellmy, R. (2005) Dominant-positive and dominant-negative heat shock factors. *Methods* 35: 199-207.

Voellmy, R. (2004) On mechanisms that control heat shock transcription factor activity in metazoan cells. *Cell Stress & Chaperones* 9: 122-133.

Voellmy, R. (2004) Transcriptional regulation of the metazoan stress protein response. *Prog. Nucleic Acid Res. Mol. Biol.* 78: 143-185.

Gough MJ, Melcher AA, Crittenden MR, Sanchez-Perez L, Voellmy R, and Vile RG. (2004) Induction of cell stress through gene transfer of an engineered heat shock transcription factor enhances tumor immunogenicity. *Gene Ther.* 11: 1099-1104.

Boellmann F, Guettouche T, Guo Y, Fenna M, Mnayer L, and Voellmy R. (2004) DAXX interacts with heat shock factor 1 during stress activation and enhances its transcriptional activity. *Proc. Natl. Acad. Sci. U S A.* 101: 4100-4105.

Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH, Browne, SE, Hall A, Voellmy R, Tsuboi Y, Dawson TM, Wolozin B, Hardy J, and Hutton M. (2004) CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. *Hum. Mol. Genet.* 13: 703-714.

Xia W, Hardy L, Liu L, Zhao S, Goodman M, Voellmy R, and Spector NL. (2003) Concurrent exposure to heat shock and H7 synergizes to trigger breast cancer cell apoptosis while sparing normal cells. *Breast Cancer Res. Treat.* 77: 233-243.

Guo, Y., Guettouche, T., Fenna, M., Boellmann, F., Pratt, W.B., Toft, D.O., Smith, D.F., and Voellmy, R. (2001) Evidence for a Mechanism of repression of heat shock factor 1 transcriptional activity by a multichaperone complex. *J.Biol.Chem.* 276, 45791-45799

Winklhofer, K.F., Reintjes, A., Hoener, M.C., Voellmy, R., and Tatzelt, J. (2001) Geldanamycin restores a defective heat shock response in vivo. *J.Biol.Chem.* 276, 45160-45167

Emiliusen, L., Gough, M., Bateman, A., Ahmed. A., Voellmy, R., Chester, J., Diaz, R.M., Harrington, K., and Vile, R. (2001) A transcriptional feedback loop for tissue-specific



expression of highly cytotoxic genes which incorporates an immunostimulatory component. *Gene Ther.* 8, 987-998

Xia, W., Voellmy, R., and Spector, N. (2000) Sensitization of tumor cells to fas killing through overexpression of heat-shock transcription factor 1. *J. Cell Physiol.* 183, 425-431.

Xia, W., Vilaboa, N., Martin, J., Mestril, R., Guo, Y., and Voellmy, R. (1999) Modulation of tolerance by mutant heat shock transcription factors, *Cell Stress & Chaperones* 4: 8-18

Tatzelt, J., Voellmy, R., and Welch, W.J. (1998) Abnormalities in stress proteins in prion diseases, *Cellular and Molecular Neurobiology* 18: 721-729

Wagstaff, M.J.D., Collaco-Moraes, Y., de Belleruche, J.S., Coffin, R.S., Voellmy, R., and Latchman, D.S. (1998) Delivery of a constitutively active form of the heat shock transcription factor using a virus vector protects neuronal cells from thermal or ischaemic stress but not from apoptosis, *Eur.J.Neuroscience* 10: 3343-3350

Zou, J., Guo, Y., Guettouche, T., Smith, D.O., and Voellmy, R. (1998) Repression of heat shock transcription factor HSF1 by Hsp90 (Hsp90 complex) that forms a stress-sensitive complex with HSF1, *Cell* 94: 471-480

Salminen, W.F., Voellmy, R., and Roberts, S.M. (1998) Effect of N-acetyl-cysteine on heat shock protein induction by acetaminophen in mouse liver. *J. Pharmacol. Exp. Ther.* 286: 519-524.

Zou, J., Salminen, W.F., Roberts, S.M., and Voellmy, R. (1998) Correlation between glutathione oxidation and trimerization of heat shock factor 1, an early step in the stress induction of the Hsp response. *Cell Stress & Chaperones* 3: 130-141

Xia, W., Guo, W., Zuo, J., and Voellmy, R. (1998) Transcriptional activation of heat shock factor 1 probed by *in vivo* phosphopeptide mapping. *J.Biol.Chem.* 273: 8749-8755

Salminen, W.F., Voellmy, R., and Roberts, S.M. (1997) Protection against hepatotoxicity by a single dose of amphetamine: the potential role of heat shock protein induction. *Toxicol. Appl. Pharmacol.* 147: 247-258

Salminen, W.F., Voellmy, R., and Roberts, S.M. (1997) Differential heat shock protein induction by acetaminophen and a non-hepatotoxic regioisomer, 3'-hydroxyacetanilide, in mouse liver. *J. Pharmacol. Exp. Ther.* 282: 1533-1540

Hardy, L., Goodman, M., Vasquez, A., Chauhan, D., Anderson, K.C., Voellmy, R., and Spector, N. (1997) Activation signals regulate heat shock transcription factor 1 in human B lymphocytes. *J. Cell. Physiol.* 170: 235-240

- Xia, W., and Voellmy, R. (1997) Hyperphosphorylation of heat shock transcription factor 1 is correlated with transcriptional competence and slow dissociation of active factor trimers. *J. Biol. Chem.* 272: 4094-102.
- Salminen, W.F., Roberts, S.M., Fenna, M., and Voellmy, R. (1997) Heat shock protein induction in murine liver after acute treatment with cocaine. *Hepatology* 25: 1147-53
- Voellmy, R. (1996) Sensing and responding to stress. In: *Stress-inducible Cellular Responses* (Feige, U., Morimoto, R.I., Yahara, I., and Polla, B., eds.) Birkhauser Verlag, Basel, Boston, Berlin, pp. 121-37
- Voellmy, R. (1996) Review of patents in the cell stress and chaperone field. *Cell Stress & Chaperones* 1: 29-32
- Baler, R., Zuo, J., and Voellmy, R. (1996) Evidence for a role of hsp70 in the regulation of the heat shock response in mammalian cells. *Cell Stress & Chaperones* 1: 33-39
- Salminen, W.F., Voellmy, R., and Roberts, S.M. (1996) Induction of hsp70 in HepG2 cells in response to hepatotoxicants. *Toxicol. Appl. Pharmacol.* 141: 117-23
- Hedge, R.S., Zuo, J., Voellmy, R., and Welch, W.J. (1995) Short circuiting stress protein expression via a tyrosine kinase inhibitor, herbimycin A. *J. Cell. Physiol.* 165: 186-200.
- Zuo, J., Rungger, D., and Voellmy, R. (1995) Multiple layers of regulation of human heat shock transcription factor 1. *Mol. Cell. Biol.* 15: 4319-30
- Black, N., Voellmy, R., and Szmant, A.M. (1995) Heat shock protein induction in Montastrea faveolata and Aiptasia pallida exposed to elevated temperatures. *Biological Bulletin* 188: 234-40
- Tatzelt, J., Voellmy, R., Zuo, J., Scott, M., Hartl, U., Prusiner, S.B.\*, and Welch, W.J. (1995) Scrapie prions selectively modify the heat shock response in neuroblastoma cells. *Proc. Natl. Acad. Sci. USA* 92: 2944-48
- Zuo, J., Baler, R., Dahl, G., and Voellmy, R. (1994) Activation of DNA-binding ability of human heat shock transcription factor 1 may involve the transition from an intramolecular to an intermolecular coiled-coil structure. *Mol. Cell. Biol.* 14: 7557-68
- Voellmy, R. (1994) Transduction of the stress signal and mechanisms of transcriptional regulation of heat shock or stress protein gene expression in higher eukaryotes. *CRC Crit. Rev. Eukaryotic Gene Expression* 4: 357-401

- Amin, J., Fernandez, M., Ananthan, J., Lis, J.T., and Voellmy, R. (1994) Cooperative binding of heat shock transcription factor to the hsp70 promoter in vivo and in vitro. J. Biol. Chem. 269: 4804-11
- Baler, R., Dahl, G., and Voellmy, R. (1993) Activation of human heat shock genes is accompanied by oligomerization, modification, and rapid translocation of heat shock transcription factor HSF1. Mol. Cell. Biol. 13: 2486-96
- Ananthan, J., Baler, R., Morrissey, D., Zuo, J., Lan, Y., Weir, M., and Voellmy, R. (1993) Synergistic activation of transcription is mediated by the N-terminal domain of Drosophila fushi tarazu homeoprotein and can occur without DNA binding by the protein. Mol. Cell. Biol. 13: 1599-609
- Schiller, P., Geffin, R., and Voellmy, R. (1992) Rapid complementation assay for anti-HIV-1 drug screening and analysis of envelope protein function. AIDS Res. Hum. Retroviruses 8: 1723-31
- Baler, R., Welch, W.J., and Voellmy, R. (1992) Heat shock gene regulation by nascent polypeptides and denatured proteins: hsp70 as a potential autoregulatory factor. J. Cell. Biol. 117: 1151-59
- Amin, J., Mestrl, R., and Voellmy, R. (1991) Genes for Drosophila small heat shock proteins are regulated differently by ecdysterone. Mol. Cell. Biol. 11: 5937-44
- Luo, Y., Amin, J., and Voellmy, R. (1991) Ecdysterone receptor is a sequence-specific transcription factor involved in the developmental regulation of heat shock genes. Mol. Cell. Biol. 11: 3660-75
- Voellmy, R., Luo, Y., Mestrl, R., Amin, J., and Ananthan, J. (1991) Mechanism of regulation of small heat shock protein genes in Drosophila. In: Heat Shock (Maresca, B., and Lindquist, S.L., eds.) Springer Verlag Heidelberg, FRG
- Goff, S.A., Voellmy, R., and Goldberg, A.L. (1988) Protein breakdown and the heat shock response. In: Ubiquitin (Rechsteiner, M. ed.) Plenum, New York, pp. 207-
- Amin, J., Ananthan, J., and Voellmy, R. (1988) Key features of heat shock regulatory elements. Mol. Cell. Biol. 8: 3761-69
- Goldenberg, C.J., Luo, Y., Fenna, M., Baler, R., Weinmann, R., and Voellmy, R. (1988) Purified human factor activates heat shock promoter in a HeLa cell-free transcription system. J. Biol. Chem. 263: 18734-39
- Schiller, P., Amin, J., Ananthan, J., Brown, M.E., Scott, W.A., and Voellmy, R. (1988) Cis-acting elements involved in the regulated expression of a human hsp70 gene. J. Mol. Biol. 203: 97-105

Brown, M.E., Amin, J., Schiller, P., Voellmy, R., and Scott, W.A. (1988) Determinants for the Dnase I - hypersensitive chromatin structure 5' to a human hsp70 gene. J. Mol. Biol. 203: 107-17

Simon, M.C., Kitchener, K., Kao, H.T., Hickey, E., Weber, L., Voellmy, R., Heintz, N., and Nevins, J.R. (1987) Selective induction of human heat shock gene transcription by the adenovirus E1A gene products, including the 13S product. Mol. Cell. Biol. 7: 2884-90

Dahl, G., Miller, T., Paul, D., Voellmy, R., and Werner, R. (1987) Expression of functional cell-cell channels from cloned rat liver gap junction complementary DNA. Science 236: 1290-3

Amin, J., Mestril, R., Schiller, P., Dreano, M., and Voellmy, R. (1987) Organization of the Drosophila melanogaster hsp70 heat shock regulation unit. Mol. Cell. Biol. 7: 1055-62

Dreano, M., Brochot, J., Myers, A., Cheng-Meyer, C., Rungger, D., Voellmy, R., and Bromley, P. (1986) High-level, heat-regulated synthesis of proteins in eukaryotic cells. Gene 49: 1-8

Mestril, R., Schiller, P., Amin, J., Klapper, H., Ananthan, J., and Voellmy, R. (1986) Heat shock and ecdysterone activation of the Drosophila melanogaster hsp23 gene: a sequence element implied in developmental regulation. EMBO J. 5: 1667-73

Ananthan, J., Goldberg, A.L., and Voellmy, R. (1986) Abnormal proteins serve as eukaryotic stress signals and trigger the activation of heat shock genes. Science 232: 522-24

Mestril, R., Rungger, D., Schiller, P., and Voellmy, R. (1985) Identification of a sequence element in the promoter of the Drosophila melanogaster hsp23 gene that is required for its heat activation. EMBO J. 4: 2971-76

Goldberg, A.L., Voellmy, R., Chung, C.H., Menon, A.S., Desautels, M., Meixsell, T., and Waxman, L. The ATP-dependent pathway for protein breakdown in bacteria and mitochondria. Prog. Clin. Biol. Res. 180: 33-45

Voellmy, R., Ahmed, A., Schiller, P., Bromley, P., and Rungger, D. (1985) Isolation and functional analysis of a human 70,000-dalton heat shock protein gene segment. Proc. Natl. Acad. Sci. USA 82: 4949-53

Lawson, R., Mestril, R., Luo, Y., and Voellmy, R. (1985) Ecdysterone selectively stimulates expression of a 23000-Da heat-shock protein-beta-galactosidase hybrid gene in cultured Drosophila cells. Dev. Biol. 110: 321-30

- Amin, J., Mestrl, R., Lawson, R., Klapper, H., and Voellmy, R. (1994) The heat shock consensus sequence is not sufficient for hsp70 gene expression in Drosophila melanogaster. Mol. Cell. Biol. 5: 197-203
- Lawson, R., Mestrl, R., Schiller, P., and Voellmy, R. (1984) Expression of heat shock-beta-galactosidase hybrid genes in cultured Drosophila cells. Mol. Gen. Genet. 198: 116-24
- Voellmy, R. (1984) The heat shock genes: a family of highly conserved genes with a superbly complex expression pattern. BioEssays 1: 213-17
- Voellmy, R., Lawson, R., Mestrl, R., and Schiller, P. (1984) In: Advances in Gene Technology: Human Genetic Disorders (Ahmad, F., Black, S., Schultz, J., and Whelan, W., eds.) ICSU Short Reports 1: 40-44
- Southgate, R., Ayme, A., and Voellmy, R. (1983) Nucleotide sequence analysis of the Drosophila small heat shock gene cluster at locus 67B. J. Mol. Biol. 165: 35-57
- Voellmy, R., Bromley, P., and Kocher, H.P. (1983) Structural similarities between corresponding heat-shock proteins from different eukaryotic cells. J. Biol. Chem. 258: 3516-22
- Voellmy, R., and Bromley, P.A. (1982) Massive heat-shock polypeptide synthesis in late chicken embryos: convenient system for study of protein synthesis in highly differentiated organisms. Mol. Cell. Biol. 2: 479-83
- Voellmy, R., and Rungger, D. (1982) Heat-induced transcription of Drosophila heat shock genes in Xenopus oocytes. In: Heat Shock from Bacteria to Man (Schlesinger, M., Ashburner, M., and Tissieres, A., eds.) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., pp. 49-56
- Voellmy, R., and Rungger, D. (1982) Transcription of a Drosophila heat shock gene is heat-induced in Xenopus oocytes. Proc. Natl. Acad. Sci. USA 79: 1776-80
- Bromley, P.A., Voellmy, R., and Spahr, P.F. (1981) Hybrid plasmids carrying part of the Rous sarcoma virus-specific leader sequence. Biochim. Biophys. Acta 655: 41-48
- Voellmy, R., Goldschmidt-Clermont, M., Southgate, R., Tissieres, A., Levis, R., and Gehring, W. (1981) A DNA segment isolated from chromosomal site 67B in D. melanogaster contains four closely linked heat-shock genes. Cell 23: 261-70
- Voellmy, R., and Goldberg, A.L. (1981) ATP-stimulated endoprotease is associated with the cell membrane in E. coli. Nature 290: 419-21

Voellmy, R., and Goldberg, A.L. (1980) Guanosine-5'-diphosphate-3'-diphosphate (ppGpp) and the regulation of protein breakdown in Escherichia coli. J. Biol. Chem. 255: 1009-14

Murakami, K., Voellmy, R., and Voellmy, R. (1979) Protein degradation is stimulated by ATP in extracts of Escherichia coli. J. Biol. Chem. 254: 8194-200

Goldberg, A.L., Voellmy, R., and Swami, K.H.S. (1979) Studies of the pathway of protein degradation in E. coli and mammalian cells. In: Biological Functions of Proteinases (Holzer, H., and Tschesche, H., eds.) Springer Verlag Germany, pp. 35-48

Voellmy, R., Murakami, K., and Goldberg, A.L. (1979) The ATP-dependent degradation of proteins in Escherichia coli and mammalian cells. In: Limited Proteolysis in Microorganisms (Cohen, G.N., and Holzer, H., eds.) Bethesda, DHEW/NIH, pp. 7-16

Voellmy, R., and Leisinger, T. (1978) Regulation of enzyme synthesis in the arginine biosynthetic pathway of Pseudomonas aeruginosa. J. Gen. Microbiol. 109: 25-35

Voellmy, R., and Utzinger, R. (1977) Immunochemical studies on acetylornithine 5-aminotransferase from Pseudomonas aeruginosa. Experientia 33: 1002-3

Voellmy, R., and Leisinger, T. (1976) Role of 4-aminobutyrate aminotransferase in the arginine metabolism of Pseudomonas aeruginosa. J. Bacteriol. 128: 722-29

Voellmy, R. (1975) Dissertation No. 5500. Zur Regulation des Argininstoffwechsels von Pseudomonas aeruginosa. ETH-Zuerich, Switzerland

Voellmy, R., and Leisinger, T. (1975) Dual role for N-2-acetylornithine 5-aminotransferase from Pseudomonas aeruginosa in arginine biosynthesis and arginine catabolism. J. Bacteriol. 122: 799-809

Voellmy, R., and Leisinger, T. (1974) Induction of N-2-acetylornithine-5-aminotransferase in Pseudomonas aeruginosa with arginine. Pathol. Microbiol. 41: 188-90

#### U.S. patents and published patent applications, and PCT applications

US 6,342,596: Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress

US 5,646,010: Methods and compositions for expression of competent eukaryotic gene products

US 5,614,381: Method for the inducible production of proteins in genetically modified eukaryotic host cells multiplied in vivo

US 5,346,812: Teratogen assay

US 20050192219: Therapies involving mutated heat shock transcription factor

US 20050130306: Viral vectors whose replication and, optionally, passenger gene are controlled by a gene switch activated by heat in the presence or absence of a small molecule regulator

US 20030008349: Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress

US 20020001629: Compositions and methods relating to prevention of chemotherapy-induced alopecia

WO2005056806: Viral vectors controlled by a gene switch

WO2003020227: Compositions and methods relating to prevention of chemotherapy-induced alopecia

WO199957290: Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress

WO199831803: Therapies involving mutated heat shock transcription factor


WO198909822: Method for the in-vivo production and testing of proteins by recombinant gene expression in selected host cells

WO198705935: Methods and compositions for expression of competent eukaryotic gene products

# **EXHIBIT B**




# Advantages of the Rat Model:



- Anagen phase comparable to humans (100% vs. 90%)
- Responsive to chemotherapies alopecic in humans
- Highly visible and definitive results
- Possibility to assess effect on malignant cells

# Protection from VP16-Induced Alopecia

No heat  
pretreatment;  
i.p. chemotherapy  
with etoposide



Localized  
protection  
at the site  
of heat  
application




Localized heat  
treatment 7 h  
prior to i.p.  
chemotherapy  
with etoposide


# Protection against Major Classes of Chemotherapy-Inducing Drug Substances

Chemotherapy agent (s)	Range(s) of concentration(s)	Route of administration	No. animals w. patch of protected fur	No. animals exposed	Frequency of protective effect
Etoposide	2.5 µg/g, twice	intraperitoneal	45	48	94%
Cyclophosphamide	35.5 µg/g, once	intraperitoneal	29	30	97%
Cyclophosphamide/ Adriamycin	20-30 µg/g once/ 2.5-4.5 µg/g twice	intraperitoneal	56	56	100%
Taxol	5 µg/animal twice	subcutaneous	7	7	100%

# Induction of Hsp70 in Hair Follicles



Unheated animal




Heat-treated animal


Skin sections from the nape of the neck of about 9-day old Sprague-Dawley rats. Sections were taken from the heat-treated area one day after heat treatment. Hsp70 immunostaining (brown; blue: counterstain)

# Transplanted Chloroleukemia Model

- Four groups of 8-day old rats (n=45) received an i.p. injection of tumor cell line MIA C51 ( $1 \times 10^5$  cells)
- Six hours later, animals received localized heat treatment
- Cyclophosphamide (35mg/kg) was administered 24 hours later



# Effect of Localized Heat on Survival Outcome



# Conclusions

- Localized application of physical inducers are an effective method for preventing chemotherapy-induced alopecia
- Localized application of physical inducers in vivo do not protect malignant cells from chemotherapy

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**